SCHEMBL20166340

SCHEMBL20166340

Cc1ccc(N)c(N2CCOCC2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGMN Q99538 4/20 0.67
PRKDC P78527 1/20 0.50
MAPT P10636 6/20 0.49
ALDH1A1 P00352 5/20 0.49
GAA P10253 5/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
RECQL P46063 2/20 0.49
POLB P06746 1/20 0.49
THRB P10828 1/20 0.49
BLM P54132 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
LMNA P02545 4/20 0.47
KDM4E B2RXH2 2/20 0.47
HTT P42858 3/20 0.45
MAPK1 P28482 2/20 0.45
PTK2B Q14289 1/20 0.45
HPGD P15428 1/20 0.44
TDP1 Q9NUW8 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3723011 0.86 ALDH1A1 (0.59) LGMNPRKDCMAPTALDH1A1GAA
SCHEMBL1339913 0.83 MAPT (0.61) LGMNMAPTALDH1A1GAAMEN1
SCHEMBL3885064 0.81 KMT2A (0.53) PRKDCMAPTALDH1A1GAAMEN1
SCHEMBL1339840 0.81 ALDH1A1 (0.65) LGMNMAPTALDH1A1GAAMEN1
SCHEMBL14280213 0.81 LGMN (0.71) LGMNMAPTALDH1A1GAAMEN1
SCHEMBL22716931 0.80 LGMN (1.00) LGMNMAPTALDH1A1GAAMEN1
SCHEMBL426323 0.80 MAPT (0.69) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL19212319 0.79 MAPT (0.53) PRKDCMAPTALDH1A1GAAL3MBTL1
SCHEMBL7591636 0.79 PRKDC (0.50) LGMNPRKDCMAPTALDH1A1GAA
SCHEMBL5825846 0.79 LGMN (0.67) LGMNPRKDCMAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4684837-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE Temple University of the Commonwealth System of Higher Education (US) 2026-01-28 EP disclosed
US-20250282790-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2025-09-11 US disclosed
EP-3541790-B1 3-(2-(4-PHENYLPIPERAZIN-1-YL)ETHYL)-2-OXA-8-AZASPIRO[4.5]DECAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS 5-HYDROXYTRYPTAMINE RECEPTOR 7 (5-HT7) MODULATORS FOR TREATING E.G. INFLAMMATORY BOWEL DISEASE, CIRCADIAN RHYTHM DISORDER OR DEPRESSION UNIV TEMPLE (US) 2025-09-03 EP disclosed
US-12338247-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-06-24 US disclosed
CN-119977980-A Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof 英联邦高等教育系统坦普尔大学 2025-05-13 CN disclosed
CN-110177776-B Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof 英联邦高等教育系统坦普尔大学 2025-02-28 CN disclosed
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND AUTOTAC INC. (KR) 2023-06-08 US disclosed
US-20230112888-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2023-04-13 US disclosed
US-11319327-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2022-05-03 US disclosed
US-20210238189-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2021-08-05 US disclosed
US-10858368-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2020-12-08 US disclosed
EP-3541790-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE Temple University - Of The Commonwealth System of Higher Education (US) 2019-09-25 EP disclosed
WO-2018093818-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282790-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR5A, HTR6 LGMN 1811/4885PRKDC 4656/4885MAPT 1607/4885
US-10858368-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use HTR7, HTR6, HTR5A LGMN 1188/4885PRKDC 4440/4885MAPT 1443/4885
US-20230112888-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR5A, HTR6 LGMN 1811/4885PRKDC 4656/4885MAPT 1607/4885
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND UBR4, UBQLN2, UBTF LGMN 1194/4885PRKDC 3130/4885MAPT 235/4885
US-11319327-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use HTR7, HTR6, HTR5A LGMN 1188/4885PRKDC 4440/4885MAPT 1443/4885
US-12338247-B2 Modulators of the 5-hydroxytryptamine receptor 7 and their method of use HTR7, HTR6, HTR5A LGMN 1188/4885PRKDC 4440/4885MAPT 1443/4885
US-20210238189-A1 NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR5A, HTR6 LGMN 1811/4885PRKDC 4656/4885MAPT 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.